The DOI matches its Crossref record; 91 of the 92 references it cites were found in a registry or an index.
Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis
Open accessAbstract
BACKGROUND Mycoplasma genitalium is now recognised as an important bacterial sexually transmitted infection. We summarised data from studies of mutations associated with macrolide and fluoroquinolone resistance in M genitalium to establish the prevalence of resistance. We also investigated temporal trends in resistance and aimed to establish the association between resistance and geographical location. METHODS In this systematic review and meta-analysis, we searched PubMed, Embase, and MEDLINE for studies that included data for the prevalence of mutations associated with macrolide and fluoroquinolone resistance in M genitalium published in any language up to Jan 7, 2019. We defined prevalence as the proportion of M genitalium samples positive for key mutations associated with azithromycin resistance (23S rRNA gene, position 2058 or 2059) or moxifloxacin resistance (S83R, S83I, D87N, or D87Y in parC), or both, among all M genitalium samples that were successfully characterised. We used random-effects meta-analyses to calculate summary estimates of prevalence. Subgroup and meta-regression analyses by WHO region and time period were done. This study was registered with PROSPERO, number CRD42016050370. RESULTS Overall, 59 studies from 21 countries met the inclusion criteria for our study: 57 studies of macrolide resistance (8966 samples), 25 of fluoroquinolone resistance (4003 samples), and 22 of dual resistance to macrolides and fluoroquinolones (3280 samples). The summary prevalence of mutations associated with macrolide resistance among M genitalium samples was 35·5% (95% CI 28·8-42·5); prevalence increased from 10·0% (95% CI 2·6-20·1%) before 2010, to 51·4% (40·3-62·4%) in 2016-17 (p<0·0001). Prevalence of mutations associated with macrolide resistance was significantly greater in samples in the WHO Western Pacific and Americas regions than in those from the WHO European region. The overall prevalence of mutations associated with fluoroquinolone resistance in M genitalium samples was 7·7% (95% CI 4·5-11·4%). Prevalence did not change significantly over time, but was significantly higher in the Western Pacific region than in the European region. Overall, the prevalence of both mutations associated with macrolide resistance and those associated with fluoroquinolone resistance among M genitalium samples was 2·8% (1·3-4·7%). The prevalence of dual resistance did not change significantly over time, and did not vary significantly by geographical region. INTERPRETATION Global surveillance and measures to optimise the efficacy of treatments-including resistance-guided strategies, new antimicrobials, and antimicrobial combination approaches-are urgently needed to ensure cure in a high proportion of M genitalium infections and to prevent further spread of resistant strains. FUNDING Australian National Health and Medical Research Council.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A systematic review of 59 studies found that the prevalence of mutations linked to macrolide resistance rose from 10% to 51% between the years prior to 2010 and the years 2016–2017 in Mycoplasma genitalium (34).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120
Hoy, D., Brooks, P., Woolf, A., Blyth, F., March, L., Bain, C., Baker, P., Smith, E., & Buchbinder, R. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.11.014 · Cited by 2,555
Wi, T., Lahra, M. M., Ndowa, F. J., Bala, M., Dillon, J. R., Ramón-Pardo, P., Eremin, S., BOLAN, G. A., & Unemo, M. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002344 · Cited by 621
Self-citationMycoplasma genitalium: from Chrysalis to Multicolored Butterfly
TAYLOR‐ROBINSON, D., & Jensen, J. S. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00006-11 · Cited by 536
Self-citationMycoplasma genitalium Infection and Female Reproductive Tract Disease: A Meta-analysis
Lis, R., Rowhani‐Rahbar, A., & Manhart, L. E. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ312 · Cited by 458
2016 European guideline on Mycoplasma genitalium infections
Jensen, J. S., Cusini, M., Gomberg, M. A., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13849 · Cited by 343
Self-citationJensen, J. S., Bradshaw, C. S., Tabrizi, S. N., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/593188 · Cited by 338
Self-citationUK national guideline for the management of gonorrhoea in adults, 2011
Bignell, C., Fitzgerald, M. G., & (Guideline Development Group) (2011) · International Journal of STD & AIDS · doi:10.1258/ijsa.2011.011267 · Cited by 269
Baumann, L., Cina, M., Egli-Gany, D., Goutaki, M., Halbeisen, F. S., Lohrer, G.-R., Ali, H., Scott, P., & Low, N. N. (2018) · Sexually Transmitted Infections · doi:10.1136/sextrans-2017-053384 · Cited by 253
Self-citation
Research works printed but not linked: 2
- Murray, 2020, Moxifloxacin and sitafloxacin treatment failure in Mycoplasma genitalium infection: association with parC mutation G248T (S83I) and concurrent gyrA utations, J Infect Dis, 221, 1017
- Jensen, 2016, 2016 European guideline on Mycoplasma genitalium infections, J Eur Acad Dermatol Venereol, 30, 1650, 10.1111/jdv.13849 · DOI
Cited by
Sorted by citations
Items 101–200 of 269
Seo, Y., Park, H., & Lee, G. (2021) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001460 · Cited by 9
Sokoll, P. R., Migliavaca, C. B., Siebert, U., Schmid, D., & Arvandi, M. (2023) · Sexually Transmitted Infections · doi:10.1136/sextrans-2022-055687 · Cited by 9
“19 The increase in cases of antimicrobial-resistant MG, especially in populations with higher exposure to the pathogen, is a public health problem that deserves attention.”
BackgroundPeris, M. P., Dehesa-García, B., Alonso, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087218 · Cited by 9
Rasul, R., McIver, R., Patel, P., Foster, R., & McNulty, A. M. (2022) · Sexually Transmitted Infections · doi:10.1136/sextrans-2021-055382 · Cited by 9
Shipitsyna, E. V., Khusnutdinova, T. А., Budilovskaya, O. V., et al. (2022) · Sexually Transmitted Infections · doi:10.1136/sextrans-2021-055249 · Cited by 9
Self-citationLee, T.-F., Lin, K., Chang, S., et al. (2022) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2022.08.009 · Cited by 9
Gardette, M., Hénin, N., Roy, C. L., et al. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.01135-22 · Cited by 9
“The high prevalence of macrolide resistance worldwide (4, 5) has resulted in an increased reliance on moxifloxacin, which is the second-line treatment; however, moxifloxacin resistance has emerged (4–7).”
BackgroundChua, T.-P., Vodstrcil, L. A., Murray, G. L., Plummer, E. L., Jensen, J. S., Unemo, M., Chow, E. P. F., Low, N. N., Whiley, D. M., Sweeney, E. L., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4764790 · Cited by 9
Self-citationQuantitation of Mycoplasma genitalium using droplet digital PCR
Peh, C. R., Danielewski, J., Chua, T.-P., Bodiyabadu, K., Machalek, D. A., Garland, S. M., Bradshaw, C. S., & Murray, G. L. (2023) · Letters in Applied Microbiology · doi:10.1093/lambio/ovad064 · Cited by 8
Self-citationManjate, A. A., Sergon, G., Kenga, D., Golparian, D., Tyulenev, Y. A., Loquilha, O., Maússe, F. E., Guschin, A. E., Langa, J. C., Passanduca, A., et al. (2024) · Frontiers in Reproductive Health · doi:10.3389/frph.2024.1323926 · Cited by 9
Self-citationAndo, N., Mizushima, D., Takano, M., et al. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae403 · Cited by 8
Abbasciano, A., Prete, R. D., Romanelli, F., et al. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-04068-3 · Cited by 8
Murray, G. L., Doyle, M. L., Bodiyabadu, K., et al. (2020) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001271 · Cited by 8
Self-citationDay, J., Afshar, B., Rowlands, R. S., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac293 · Cited by 8
Self-citationEdelstein, I. A., Guschin, A. E., Romanov, A. V., et al. (2023) · Pathogens · doi:10.3390/pathogens12030496 · Cited by 8
He, W., Yuan, Y., Liang, J., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1271392 · Cited by 7
Point-of-Care Amenable Detection of Mycoplasma genitalium and Its Antibiotic Resistance Mutations
Chen, F., Wang, J., Nambiar, A. H., et al. (2023) · ACS Sensors · doi:10.1021/acssensors.2c02630 · Cited by 7
Peramuna, T., Kim, C. M., Aguila, L. K. T., Wendt, K. L., Wood, G. E., & Cichewicz, R. H. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.4c00209 · Cited by 7
Dong, B., Hu, K., Mao, Y., et al. (2024) · Food Chemistry · doi:10.1016/j.foodchem.2024.140419 · Cited by 7
Johnson, K., Buluwela, E., McDonald, G., et al. (2024) · Sexually Transmitted Infections · doi:10.1136/sextrans-2023-056093 · Cited by 7
The fungal natural product fusidic acid demonstrates potent activity against Mycoplasma genitalium
Wood, G. E., Lee, J. W., Peramuna, T., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01006-24 · Cited by 7
“%) have resulted in the appearance of multidrug-resistant strains (4).”
BackgroundXu, X., Bradshaw, C. S., Chow, E. P. F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90627-3 · Cited by 7
Self-citationMetal utilization in genome-reduced bacteria: Do human mycoplasmas rely on iron?
Perálvarez‐Marín, A., Baranowski, É., Bierge, P., Pich, Ò. Q., & Lebrette, H. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.10.022 · Cited by 9
“The prevalence of mutations associated with macrolide-resistance in Mge is also rapidly increasing globally [105] in line with the observed decrease of macrolide efficacy in the treatment of Mge infections [106].”
BackgroundSpiller-Boulter, O., Paukner, S., Boostrom, I., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10111370 · Cited by 7
“hominis), as they have a limited repertoire of therapeutics and prevalence of macrolide resistance is increasing in ureaplasmas as well [31].”
BackgroundBalish, M. F., Chopra‐Dewasthaly, R., Pereyre, S., Ramírez, A. S., Viver, T., & Spergser, J. (2024) · Wiley eBooks · doi:10.1002/9781118960608.gbm01263.pub3 · Cited by 7
Mycoplasma genitalium’s Antibiotic Resistance in Sexually Transmitted Infections Clinics in Israel
Azrad, M., Saleh, N., Zur, I. Y., et al. (2024) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000828 · Cited by 6
Wong, N. S., Wong, B. C. K., Chan, D. P.-C., Cheung, D. K. F., To, H. K. W., Chung, S. L., Ip, M., & Lee, S. S. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf158 · Cited by 6
“13 To date, only a few studies have estimated the prevalence of M . genitalium RAMs in MSM with HIV.”
High macrolides and fluoroquinolones resistance rate in Mycoplasma genitalium in southern Tenerife
León, C. M., de Artola, D. G.-M., & Pino-Calm, B. (2023) · Revista Española de Quimioterapia · doi:10.37201/req/014.2023 · Cited by 6
“La principal alternativa terapéutica son las fluoroquinolonas, con un porcentaje de resistencias mucho menor (7-10%) [4], siendo la pauta más aceptada moxifloxacino 400 mg/día”
BackgroundLara, I., Hernandez-Ruiz, V., Fernández-Huerta, M., et al. (2025) · Sexually Transmitted Infections · doi:10.1136/sextrans-2024-056374 · Cited by 6
Gerwen, O. T. V., Griner, S. B., Davis, A., et al. (2022) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000001651 · Cited by 6
Baetselier, I. D., Vuylsteke, B., Cuylaerts, V., Cuer, B., Yaya, I., Mensah, E., Dah, E. T. T., Anoma, C., Koné, A., Diandé, S., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac615 · Cited by 6
“Besides the high prevalence of MG, we also report on the presence of RAMs to macrolides and fluoroquinolones in MG among African MSM, which was previously mostly documented in high-resource settings [11, 14].”
BackgroundInfluentialEngage Study Team, Lê, A.-S., Labbé, A., et al. (2023) · Canada Communicable Disease Report · doi:10.14745/ccdr.v49i1112a03 · Cited by 6
“Mycoplasma genitalium co-infection with other bacterial sexually transmitted infections (STIs) has been frequently reported in gbMSM (7,9).”
BackgroundInfluentialVodstrcil, L. A., Htaik, K., Plummer, E. L., et al. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.101005 · Cited by 6
Self-citationKato, H., Hagihara, M., Asai, N., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11030353 · Cited by 6
“genitalium with parC (quinolone resistance-associated mutation, QRM) was 8% and did not change over time [24].”
BackgroundEdelstein, I. A., Gushchin, A. E., Гладин, Д. П., et al. (2024) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2024.3.356-369 · Cited by 5
Adriaens, N., Bouwman, F. M., Bruisten, S. M., et al. (2025) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001999 · Cited by 5
“Furthermore, the increased prevalence of antibiotic resistance in MSM populations may have created a stronger selective pressure on M. genitalium isolates, leading to more frequent mutations [23].”
Peramuna, T., Wood, G. E., Hu, Z., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00386 · Cited by 5
Maldonado-Barrueco, A., Rodríguez-Ayala, M., Grandioso-Vas, D., García-Clemente, P., Guedez-López, G. V., García‐Rodríguez, J., & Quiles‐Melero, I. (2023) · Revista Española de Quimioterapia · doi:10.37201/req/123.2022 · Cited by 5
“However, we have not found any predominant resistance mutations in patients with any STCs. Studies reported in other areas of Spain showed a prevalence of macrolides resistance in MG of around 25-30% [6- 9].”
BackgroundInfluentialButcher, R., Jarju, S., Obayemi, D., Bashorun, A. O., Vasileva, H., Bransbury-Hare, H., Agboghoroma, O., Drammeh, L., Holland, M. J., Harding-Esch, E. M., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08399-2 · Cited by 5
“However, in a systematic review of mutations associated with macrolide and fluoroquinolone resistance in M. genitalium, AMR data for the African region were only available from Kenya and South Africa [45].”
BackgroundTulsiani, S. M., Anagrius, C., Loré, B., et al. (2023) · Sexually Transmitted Infections · doi:10.1136/sextrans-2023-055900 · Cited by 5
Self-citationMullis, C. E., Marlow, K. A., Maity, A., et al. (2023) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000001911 · Cited by 5
“13 The prevalence of macrolide resistance mutations is >50% in a meta-analysis of 59 studies from 21 countries.”
BackgroundInfluentialVanbaelen, T., Laumen, J., Dijck, C. V., de Block, T., Manoharan-Basil, S. S., & Kenyon, C. R. (2024) · Antibiotics · doi:10.3390/antibiotics13020188 · Cited by 4
Azithromycin and moxifloxacin resistance determinants in Mycoplasma genitalium in Lleida, Spain
García, L. F., Arnuelos, J. A., González, É. L., et al. (2024) · Revista Española de Quimioterapia · doi:10.37201/req/015.2024 · Cited by 5
“A previous azithromycin treatment for an STI or respiratory infection could explain the high resistance associated with azithromycin treatment [7,9,15].”
BackgroundHackett, A., Yossepowitch, O., Goor, Y., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164924 · Cited by 5
“FQ resistance remained stable over that time at 7.7% [18].”
BackgroundResultInfluentialHuaman, J. L., Bradshaw, C. S., Chua, T.-P., et al. (2025) · Journal of Medical Microbiology · doi:10.1099/jmm.0.002040 · Cited by 5
“Moreover, the prevalence for resistance markers to first-and second-line antibiotics (macrolides and fluoroquinolones, respectively) is increasing globally [7, 8].”
Self-citationRivaya, B., Roy, C. L., Jordana‐Lluch, E., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11040485 · Cited by 5
“However, our results are concordant with the lower FQr prevalence detected in WHO European regions, in comparison with Western Pacific territories [21].”
BackgroundResultMycoplasma genitaliummacrolide and fluoroquinolone resistance in pregnant women in Papua New Guinea
Jonduo, M., Vallely, A. J., Whiley, D. M., et al. (2022) · Sexually Transmitted Infections · doi:10.1136/sextrans-2022-055552 · Cited by 5
Self-citationEdelstein, I. A., Romanov, A. V., & Kozlov, R. S. (2023) · Microbial Drug Resistance · doi:10.1089/mdr.2022.0131 · Cited by 5
Seña, A. C., Matoga, M., Yang, L., López‐Medina, E., Aghakhanian, F. F., Chen, J. S., Bettin, E. B., Caimano, M. J., Chen, W., Luna, J. A. G., et al. (2023) · medRxiv · doi:10.1101/2023.07.19.23291250 · Cited by 5
Chromy, D., Starossek, L., Grabmeier‐Pfistershammer, K., Adamek, S., Maischack, F., Sammet, S., Sadoghi, B., Stary, G., Willinger, B., Weninger, W., et al. (2024) · Infection · doi:10.1007/s15010-024-02261-6 · Cited by 4
Philipova, I. O., Mademova, M., Birindjieva, E., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14232665 · Cited by 4
“…European countries, North America, East Asia and Australia, the increasing treatment failures with azithromycin in M. genitalium over the last 15 years have been consistent with the increases in the prevalence of macrolide-resistance mutations from 10% before 2010 to more than 50% in 2024 [10,12].”
Moreno‐Flores, A., Domínguez-Landesa, M., Fernández, L. S., et al. (2024) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2024.10.006 · Cited by 4
JMM Profile: Mycoplasma genitalium: a small, yet significant pathogen
Rudman, T., Rowlands, R. S., Jensen, J. S., et al. (2025) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001984 · Cited by 4
“Fluoroquinolone resistance rates are lower in Europe, but dual resistance to macrolides and fluoroquinolones is not uncommon [33].”
Self-citationGullsby, K., Lindh, L., Adriaenssens, R., et al. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115349 · Cited by 4
Pérez‐Prieto, I., Skafte-Holm, A., & Jensen, J. S. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.914874 · Cited by 4
Self-citationMonitoring of macrolide resistanceassociated mutations in Mycoplasma genitalium in Russia
Edelstein, I. A., Руднева, Н. С., Romanov, A. V., et al. (2022) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2022.1.52-60 · Cited by 4
Ngobese, B., Swe-Han, K. S., Tinarwo, P., et al. (2022) · International Journal of STD & AIDS · doi:10.1177/09564624221129412 · Cited by 4
“genitalium poses a considerable problem for clinical practice and public health worldwide.(12) Limited data are available on the prevalence of mutations associated with macrolide resistance in South Africa, with only few retrospective studies reporting the prevalence rate of mutations in the 23S rRNA gene ofM.”
BackgroundCost-effectiveness of testing forMycoplasma genitaliumamong men who have sex with men in Australia
Ong, J. J., Lim, A. G., Bradshaw, C. S., et al. (2023) · Sexually Transmitted Infections · doi:10.1136/sextrans-2022-055611 · Cited by 4
“This includes the costs of treating resistant infections, increased morbidity and mortality, or the cost of developing new therapies, which are the major drivers of costs related to AMR.17 This hypothetical AMR tax was added as an extra cost variable with each single treatment of MG.”
BackgroundInfluentialSelf-citationMycoplasma genitalium Endocarditis in Prosthetic Aortic Valve
Ramakrishnan, G., Kronig, I., Gaïa, N., et al. (2023) · Emerging infectious diseases · doi:10.3201/eid2910.221639 · Cited by 4
Successful Treatment of Mycoplasma genitalium Urethritis With High-Dose Tinidazole
Liscynesky, C., Lipps, A., & Bazan, J. A. (2024) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000002101 · Cited by 4
Trends of Mycoplasma genitalium infections in Berlin, Germany, 2017–2023
Dumke, R., & Glaunsinger, T. (2024) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2024.12.020 · Cited by 4
Philipova, I. O., Hadad, R., Levterova, V., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19067 · Cited by 4
Self-citationRheumatic disease management in the Campania region of Italy during the COVID-19 pandemic
Masini, F., Gjeloshi, K., Ferrara, R., et al. (2020) · Rheumatology International · doi:10.1007/s00296-020-04648-8 · Cited by 4
Sexually Transmitted Diseases: An Overview
Hughes, Y., & Sawleshwarkar, S. (2022) · Wiley eBooks · doi:10.1002/9781119826781.ch1 · Cited by 5
Molecular epidemiology and antimicrobials resistance mechanism of Mycoplasma genitlaium
Shedko, E. D., Goloveshkina, E. N., & Акимкин, В. Г. (2021) · Vestnik dermatologii i venerologii · doi:10.25208/vdv1192 · Cited by 3
Kawaguchi, H., Nakura, Y., Yamamoto, R., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0306958 · Cited by 3
Prevalence of Mycoplasma genitalium in a Southern California patient population
Tran, A., Amamoto, A., Bates, M., Leonard, J., Carrico, V., & Pride, D. T. (2025) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2025.117130 · Cited by 3
Maldonado-Barrueco, A., Sanz-González, C., Falces‐Romero, I., et al. (2023) · Revista Española de Quimioterapia · doi:10.37201/req/058.2023 · Cited by 3
“The resistance rates to macrolides and fluoroquinolones are well known for Mycoplasma genitalium infections due to the large supply of commercially available assays [5-7].”
BackgroundAndo, N., Mizushima, D., Shimizu, Y., et al. (2023) · JMIR Research Protocols · doi:10.2196/52565 · Cited by 3
“The prevalence of macrolide resistance-associated mutations (MRMs) has increased over the decades [2].”
Ljubin-Šternak, S., Meštrović, T., Marijan, T., et al. (2024) · Genes · doi:10.3390/genes15040470 · Cited by 3
“…of mutations associated with resistance was then determined by summing the samples with at least one key mutation in either the 23S RNA or parC gene (numerator) and dividing by the total number of M. genitalium -positive samples successfully characterized for the respective gene (denominator) [9].”
BackgroundMethodInfluentialMycoplasma genitalium Infections and Associated Antimicrobial Resistance in Canada, 1980–2023
Copete, Á. R., Herrera, M., Suarez-Ariza, C., et al. (2025) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed10050139 · Cited by 3
“Macrolides, initially recommended as the first line of treatment, are now threatened due to over 50% macrolide resistance in M. genitalium isolates in Canada [16] and 80% in other countries [17].”
InfluentialEmerging macrolide resistance in Mycoplasma genitalium
Cools, P., & Padalko, E. Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30462-x · Cited by 3
Hahn, A., Frickmann, H., & Loderstädt, U. (2021) · Antibiotics · doi:10.3390/antibiotics10080929 · Cited by 3
“years became an issue of therapeutic concern as well [8,9], making the application of less effective therapeutic alternatives, such as pristinamycin, necessary [10–12].”
BackgroundArgamasilla, A. A. T., Jordán, J. M., & Moreno‐Docón, A. (2022) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2022.04.017 · Cited by 3
Blanco, P., Rachline, A., Tarantola, A., et al. (2022) · International Journal of STD & AIDS · doi:10.1177/09564624221103808 · Cited by 3
“Conversely, some countries in the South Pacific, such as Australia, have some of the highest resistance rates described worldwide.(19)”
BackgroundAntibiotic Dispensing During First Year of COVID-19 Pandemic In Brazilian Public Hospitals
Pereira, M. L., Mothé, D. A. C., Pinheiro, K. D. S., Gonçalves, S. S., & dos Santos, K. V. (2023) · Future Microbiology · doi:10.2217/fmb-2022-0255 · Cited by 3
Obafemi, O. A., Rowan, S. E., Nishiyama, M., et al. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.07.004 · Cited by 3
Urethritis – Erregerspektrum, Diagnostik und Therapie
Buder, S. C. (2023) · Die Dermatologie · doi:10.1007/s00105-023-05230-6 · Cited by 4
Prevalence of Urogenital Mycoplasma genitalium Infection at 2 US Army Medical Facilities
Romo, M. L., Moreland, S. C., Yates, A., et al. (2024) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000001947 · Cited by 3
Nguyen, K. D., Adamson, P. C., Bui, H. T. M., et al. (2024) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000002056 · Cited by 3
“20,21 Detection of M. genitalium infections is through the use of nucleic acid amplification tests (NAATs).”
Nadal‐Barón, P., Trejo-Zahínos, J., Arando, M., Barberan-Masegosa, A., Bernat‐Sole, M., Pérez-Ugarte, A., Villatoro, A. M., Alcubilla, P., Sulleiro, E., González‐López, J. J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-74355-y · Cited by 3
“Although macrolides are no longer recommended for syphilis treatment, resistant strains remain highly prevalent suggesting that resistance may be driven by antibiotic use for other infections 30 .”
BackgroundKobori, Y., Yoshida, N., Manda, K., et al. (2025) · International Journal of Urology · doi:10.1111/iju.70046 · Cited by 3
“Macrolide resistance-associated mutations (MRMs) have been increasing over the past decades, especially in the Americas and the Western Pacific region [2].”
Schröder, D., Sorano, S., Shipitsyna, E. V., et al. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1576376 · Cited by 3
Self-citationAntimicrobial resistance: review
Moutafchieva, R., & Mladenov, D. (2020) · Trakia Journal of Sciences · doi:10.15547/tjs.2020.04.015 · Cited by 3
Bach, S. (2022) · The Nurse Practitioner · doi:10.1097/01.npr.0000873540.82933.f0 · Cited by 3
Bodiybadu, K., Danielewski, J., Plummer, E. L., et al. (2022) · Letters in Applied Microbiology · doi:10.1093/lambio/ovac002 · Cited by 3
Self-citationLeukocyturia and Sexually Transmitted Infections: A Cohort Study of 2236 Asymptomatic Adults
Corgie, L., Huiban, N., Janvier, F., Darles, C., Brocq, F.-X., Dutasta, F., & Monteil, M. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.023 · Cited by 2
Zhang, Y., Vodstrcil, L. A., Htaik, K., Plummer, E. L., Petra, V. D., Sen, M. G., Williamson, D. A., Owlad, M., Murray, G. L., Chow, E. P. F., et al. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.05.004 · Cited by 2
Self-citationAvchinnikova, D. A., Edelstein, I. A., Николаевна, П. В., et al. (2024) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2024.2.201-207 · Cited by 2
Fox‐Lewis, S., Forster, R. F., Basu, I., et al. (2024) · Sexual Health · doi:10.1071/sh24166 · Cited by 2
Wijekoon, D., Chen, M. Y., Hughes, Y., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf107 · Cited by 2
Self-citationYu, C., Lu, B., Tang, Y., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.162464 · Cited by 2
Horvath, L., Juan, P., Lorente, X., de Vega, I. F., Golf, N., Vergara, A., de Loredo, N., García-Fernández, D., Montoya, F. A. D. L. S., del Carlo, G., et al. (2025) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2025.151667 · Cited by 2
Chlamydia trachomatis and Mycoplasma genitalium
Joly, A., & Rayment, M. (2025) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2025.09.008 · Cited by 2
Antimicrobial resistance crisis in STIs: Gonorrhea and M. genitalium on the brink of untreatability
Ghodsi, N., Arezoomand, R., & Azimian, A. (2026) · New Microbes and New Infections · doi:10.1016/j.nmni.2026.101747 · Cited by 2
“The situation is particularly alarming for Neisseria gonorrhoeae , where even last-resort empirical monotherapy (injectable ceftriaxone) is under threat, and for Mycoplasma genitalium , which has few treatment options and where untreatable infections have already been reported [8,9].”
Doxycycline: the universal treatment for anogenital chlamydia
Fairley, C. K., Hocking, J. S., & Kong, F. Y. S. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00173-6 · Cited by 2
Self-citationBalgovind, P., Atchison, S., Danielewski, J., et al. (2023) · Letters in Applied Microbiology · doi:10.1093/lambio/ovad124 · Cited by 2
Self-citationDoxycycline in STI Prophylaxis—A Literature Review
Załęski, A., Sapuła, M., Lembas, A., & Wiercińska‐Drapało, A. (2023) · Venereology · doi:10.3390/venereology3010001 · Cited by 2
“This species of bacterium is characterized by its extraordinary ability to develop antibiotic resistance to multiple agents [19,42].”
BackgroundShrestha, S., Thapa, R. B., Adhikari, P., et al. (2024) · Bulletin of pioneering researches of medical and clinical science · doi:10.51847/bckw7uo27g · Cited by 2
Evaluation of molecular testing for Mycoplasma genitalium for symptomatic women
Brehony, C., Eogan, M., Lambert, J. S., et al. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02782-1 · Cited by 2
Metadata
- Authors
- Machalek, D. A., Tao, Y., Shilling, H., Jensen, J. S., Unemo, M., Murray, G., Chow, E. P. F., Low, N., Garland, S. M., Vodstrcil, L. A., Fairley, C. K., Hocking, J. S., Zhang, L., & Bradshaw, C. S.
- Affiliations
- Royal Women's Hospital (AU)
- The Alfred Hospital (AU)
- Statens Serum Institut (DK)
- Örebro University (SE)
- University of Bern (CH)
- The University of Melbourne (AU)
- Corresponding author
- Machalek, Dorothy A
- ORCID
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 20
- Issue
- 11
- Pages
- 1302-1314
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W3038888845
- Semantic Scholar
- 121969556aa4999049ccb6b492ce88b5ce6d7302
- Cited by
- 273
- References
- 92
- Citations by year
- 2026: 22 · 2025: 32 · 2024: 56 · 2023: 61 · 2022: 50 · 2021: 36 · 2020: 16
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- BORIS (University Library Bern) (submittedVersion, cc-by-nc-nd)
- Open Access CRIS of the University of Bern
- Funders
- Australian Government
- Nabriva Therapeutics
- Department of Industry, Innovation and Science, Australian Government
- Seqirus
- Medical Research Council
- National Health and Medical Research Council (568971)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Life Sciences › Immunology and Microbiology › Microbiology › Microbial infections and disease research
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- Mycoplasma genitalium, macrolide resistance, fluoroquinolone resistance, antimicrobial resistance, 23S rRNA mutations, parC mutations, azithromycin resistance, moxifloxacin resistance, dual resistance, sexually transmitted infections, prevalence trends, WHO regions, resistance trends, antimicrobial susceptibility testing
- MeSH terms
- Moxifloxacin, Anti-Bacterial Agents, Carrier Proteins, Female, Humans, Male, Mutation, Mycoplasma Infections, RNA, Ribosomal, 23S, Transferases, Sexually Transmitted Diseases, Bacterial, Prevalence, Azithromycin, Polymorphism, Single Nucleotide, Drug Resistance, Bacterial, Mycoplasma genitalium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
